Nivolumab and Ipilimumab +/-UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)

被引：0

作者：

Haakensen, V. ^{[1
]}

Nowak, A. ^{[2
]}

Ellingsen, E. ^{[3
]}

Grundberg, O. ^{[4
]}

Farooqi, S. ^{[1
]}

Mcculloch, T. ^{[5
]}

Cedres, S. ^{[6
]}

Bjaanaes, M. ^{[1
]}

Helland, A. ^{[7
,8
]}

机构：

[1] Oslo Univ Hosp, Div Canc Med, Oslo, Norway

[2] Univ Western Australia, Natl Ctr Asbestos Related Dis, Crawley, ACT, Australia

[3] Ultimovacs Asa, Oslo, Norway

[4] Karolinska Inst, Stockholm, Sweden

[5] Aalborg Univ Hosp, Aalborg, Denmark

[6] Vall Dhebron Inst Oncol Vhio, Med Oncol, Vall Dhebron Barcelona Hosp Campus, Barcelona, Spain

[7] Univ Oslo, Clin Med, Oslo, Norway

[8] Oslo Univ Hosp, Oslo, Norway

来源：

关键词：

Immunotherapy; Mesothelioma; clinical trial;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P24.07

引用

页码：S380 / S380

页数：1